Notably, previous studies have also suggested the potential utility of FNDC3B as a prognostic biomarker across several cancers including cervical cancer, hepatocellular carcinoma, colorectal cancer and glioblastoma [32, 34–36]. This evidence concerns the gene FNDC3B and glioblastoma.